- Home
- DRRX vs MIRM Comparison
DRRX vs MIRM Comparison
Compare DRRX & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRRX
- MIRM
- Stock Information
- Founded
- DRRX 1998
- MIRM 2018
- Country
- DRRX United States
- MIRM United States
- Employees
- DRRX N/A
- MIRM N/A
- Industry
- DRRX Biotechnology: Pharmaceutical Preparations
- MIRM Biotechnology: Pharmaceutical Preparations
- Sector
- DRRX Health Care
- MIRM Health Care
- Exchange
- DRRX Nasdaq
- MIRM Nasdaq
- Market Cap
- DRRX N/A
- MIRM 1.9B
- IPO Year
- DRRX 2000
- MIRM 2019
- Fundamental
- Price
- DRRX $0.67
- MIRM $45.27
- Analyst Decision
- DRRX Hold
- MIRM Strong Buy
- Analyst Count
- DRRX 1
- MIRM 11
- Target Price
- DRRX N/A
- MIRM $58.55
- AVG Volume (30 Days)
- DRRX 99.9K
- MIRM 412.6K
- Earning Date
- DRRX 05-20-2025
- MIRM 05-07-2025
- Dividend Yield
- DRRX N/A
- MIRM N/A
- EPS Growth
- DRRX N/A
- MIRM N/A
- EPS
- DRRX N/A
- MIRM N/A
- Revenue
- DRRX $2,031,000.00
- MIRM $379,251,000.00
- Revenue This Year
- DRRX N/A
- MIRM $29.51
- Revenue Next Year
- DRRX $935.93
- MIRM $20.27
- P/E Ratio
- DRRX N/A
- MIRM N/A
- Revenue Growth
- DRRX N/A
- MIRM 69.31
- 52 Week Low
- DRRX $0.52
- MIRM $23.83
- 52 Week High
- DRRX $1.88
- MIRM $54.23
- Technical
- Relative Strength Index (RSI)
- DRRX 44.97
- MIRM 63.46
- Support Level
- DRRX $0.52
- MIRM $40.00
- Resistance Level
- DRRX $0.67
- MIRM $47.43
- Average True Range (ATR)
- DRRX 0.06
- MIRM 2.00
- MACD
- DRRX 0.00
- MIRM 0.67
- Stochastic Oscillator
- DRRX 59.09
- MIRM 88.68
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.